1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials. Issue 5 (6th June 2022) Authors: Martino, Enrica Antonia; Conticello, Concetta; Zamagni, Elena; Pavone, Vincenzo; Palmieri, Salvatore; Musso, Maurizio; Tacchetti, Paola; Mele, Anna; Catalano, Lucio; Vigna, Ernesto; Bruzzese, Antonella; Mendicino, Francesco; Botta, Cirino; Vincelli, Iolanda Donatella; Farina, Giuliana; Barone, Ma... Journal: Hematological oncology Issue: Volume 40:Issue 5(2022) Page Start: 1009 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Issue 1 (January 2023) Authors: Mina, Roberto; Musto, Pellegrino; Rota-Scalabrini, Delia; Paris, Laura; Gamberi, Barbara; Palmas, Angelo; Aquino, Sara; de Fabritiis, Paolo; Giuliani, Nicola; De Rosa, Luca; Gozzetti, Alessandro; Cellini, Claudia; Bertamini, Luca; Capra, Andrea; Oddolo, Daniela; Vincelli, Iolanda Donatella; Ronco... Journal: Lancet oncology Issue: Volume 24:Issue 1(2023) Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Issue 12 (December 2021) Authors: Gay, Francesca; Musto, Pellegrino; Rota-Scalabrini, Delia; Bertamini, Luca; Belotti, Angelo; Galli, Monica; Offidani, Massimo; Zamagni, Elena; Ledda, Antonio; Grasso, Mariella; Ballanti, Stelvio; Spadano, Antonio; Cea, Michele; Patriarca, Francesca; D'Agostino, Mattia; Capra, Andrea; Giuliani, Ni... Journal: Lancet oncology Issue: Volume 22:Issue 12(2021) Page Start: 1705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. (December 2018) Authors: D'Agostino, Mattia; De Paoli, Lorenzo; Conticello, Concetta; Offidani, Massimo; Ria, Roberto; Petrucci, Maria Teresa; Spada, Stefano; Marcatti, Magda; Catalano, Lucio; Gilestro, Milena; Guglielmelli, Tommasina; Baldini, Luca; Gamberi, Barbara; Rizzi, Rita; De Sabbata, Giovanni; Di Renzo, Nicola; ... Journal: Critical reviews in oncology/hematology Issue: Volume 132(2018) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. Issue 4 (1st June 2022) Authors: Bruzzese, Antonella; Derudas, Daniele; Galli, Monica; Martino, Enrica Antonia; Rocco, Stefano; Conticello, Concetta; Califano, Catello; Giuliani, Nicola; Mangiacavalli, Silvia; Farina, Giuliana; Lombardo, Alessandra; Brunori, Marino; Rossi, Elena; Antonioli, Elisabetta; Ria, Roberto; Zambello, Re... Journal: Hematological oncology Issue: Volume 40:Issue 4(2022) Page Start: 704 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Issue 10292 (19th June 2021) Authors: Moreau, Philippe; Dimopoulos, Meletios-Athanasios; Mikhael, Joseph; Yong, Kwee; Capra, Marcelo; Facon, Thierry; Hajek, Roman; Špička, Ivan; Baker, Ross; Kim, Kihyun; Martinez, Gracia; Min, Chang-Ki; Pour, Ludek; Leleu, Xavier; Oriol, Albert; Koh, Youngil; Suzuki, Kenshi; Risse, Marie-Laure; Asset... Journal: Lancet Issue: Volume 397:Issue 10292(2021) Page Start: 2361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Issue 5 (18th December 2018) Authors: Gambella, Manuela; Omedé, Paola; Spada, Stefano; Muccio, Vittorio Emanuele; Gilestro, Milena; Saraci, Elona; Grammatico, Sara; Larocca, Alessandra; Conticello, Concetta; Bernardini, Annalisa; Gamberi, Barbara; Troia, Rossella; Liberati, Anna Marina; Offidani, Massimo; Rocci, Alberto; Palumbo, Ant... Journal: Cancer Issue: Volume 125:Issue 5(2019) Page Start: 750 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗